Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lori Gautreaux

Internal Medicine Lafayette, LA Medical Doctor

NPI 1942576855 CMS profile 1401604

4640 W Congress St, Lafayette, LA 70506

Open in the dashboard

General payments

$3,365

215 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lori Gautreaux of Lafayette, LA is reported in the CMS Open Payments database as having received $3,365 across 215 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $359 19
2024 General $937 59
2023 General $438 28
2022 General $354 22
2021 General $590 40
2020 General $470 31
2019 General $218 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lori Gautreaux
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Lori Gautreaux were reported at $359. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Lori Gautreaux Internal Medicine median Middle half National median
2019 $218 $159 $48–$570 $163
2020 $470 $119 $33–$402 $114
2021 $590 $135 $37–$521 $132
2022 $354 $141 $42–$496 $149
2023 $438 $149 $45–$519 $160
2024 $937 $154 $47–$537 $164
2025 $359 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $606 42 payments
  2. GlaxoSmithKline, LLC. $309 19 payments
  3. Lilly USA, LLC $265 18 payments
  4. Sumitomo Pharma America, Inc. $247 19 payments
  5. Novo Nordisk Inc $230 15 payments
  6. AstraZeneca Pharmaceuticals LP $207 11 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $107 6 payments
  8. Esperion Therapeutics, Inc. $104 6 payments
  9. Amgen Inc. $97 7 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $96 7 payments
  11. Other $1,097 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,350 214 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. GEMTESA $247 19 payments
  2. Ozempic $230 15 payments
  3. VRAYLAR $220 17 payments
  4. TRELEGY ELLIPTA $212 13 payments
  5. UBRELVY $185 13 payments
  6. QULIPTA $173 10 payments
  7. TRULICITY $162 11 payments
  8. FARXIGA $151 8 payments
  9. RYBELSUS $150 10 payments
  10. LINZESS $134 9 payments
  11. Other $2,287 142 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 198 drugs

Part D claims

16,413

Median for Internal Medicine: 777

Drug cost

$1,345,319

Median for Internal Medicine: $73,373

Branded share of claims

21.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 201 $270,836
Mounjaro Tirzepatide Brand 115 $125,832
Trulicity Dulaglutide Brand 83 $124,273
Jardiance Empagliflozin Brand 61 $77,119
Linzess Linaclotide Brand 88 $76,132
Farxiga Dapagliflozin Propanediol Brand 87 $73,851
Januvia Sitagliptin Phosphate Brand 76 $71,050
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 52 $48,359
Eliquis Apixaban Brand 40 $34,770
Vraylar Cariprazine Hcl Brand 21 $30,536

The 10 drugs with the highest cost, of 198 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$323,880

Of which drugs: $5,449

Medicare patients

352

Average age 75

Services billed

7,601

230 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 56%
Diabetes 48%
Ischemic heart disease 33%
Depression 30%
COPD 29%
Chronic kidney disease 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 61 61 $4,991
Injection, ketorolac tromethamine, per 15 mg J1885 Office 11 23 $11
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 20 80 $7
Injection, ceftriaxone sodium, per 250 mg J0696 Office 18 18 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $169
$169 23 —
NEXLETOL
  • Esperion Therapeutics, Inc. $76
$76 — —
IBSRELA
  • Ardelyx, Inc. $63
$63 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $46
  • AbbVie, Inc. $12
$57 88 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

215 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record